Heron Therapeutics, Inc. (HRTX)

NASDAQ: HRTX · IEX Real-Time Price · USD
2.740
+0.140 (5.38%)
At close: Feb 27, 2024, 4:00 PM
2.760
+0.020 (0.73%)
After-hours: Feb 27, 2024, 7:58 PM EST
5.38%
Market Cap 390.19M
Revenue (ttm) 122.84M
Net Income (ttm) -119.70M
Shares Out 150.07M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,960,227
Open 2.650
Previous Close 2.600
Day's Range 2.580 - 2.755
52-Week Range 0.500 - 2.990
Beta 1.67
Analysts Strong Buy
Price Target 7.00 (+155.47%)
Earnings Date Mar 21, 2024

About HRTX

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycli... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 1987
Employees 203
Stock Exchange NASDAQ
Ticker Symbol HRTX
Full Company Profile

Financial Performance

In 2022, HRTX's revenue was $107.67 million, an increase of 24.70% compared to the previous year's $86.35 million. Losses were -$182.02 million, -17.52% less than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 155.47% from the latest price.

Price Target
$7.0
(155.47% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

– Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually – SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biote...

5 weeks ago - PRNewsWire

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

SAN DIEGO , Jan. 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership...

7 weeks ago - PRNewsWire

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of $99 million to $103 million We anticipate...

3 months ago - PRNewsWire

Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023

SAN DIEGO , Nov. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...

4 months ago - PRNewsWire

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise Favorable outcome at Markman hearing in pending CINVANTI® ANDA patent litigati...

7 months ago - PRNewsWire

Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...

7 months ago - PRNewsWire

Heron Therapeutics Announces Cost Reduction Plan and Restructuring

- Expected overall cash savings of $75 million through 2025 - New executive management team in place SAN DIEGO , July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-sta...

7 months ago - PRNewsWire

Heron Therapeutics Announces $30 Million Private Placement Financing

SAN DIEGO , July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing...

Other symbols: HTGC
7 months ago - PRNewsWire

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

SAN DIEGO , June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat...

8 months ago - PRNewsWire

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer

SAN DIEGO , June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat...

9 months ago - PRNewsWire

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022.

10 months ago - PRNewsWire

Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

SAN DIEGO , May 4, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatme...

10 months ago - PRNewsWire

Heron Therapeutics Announces Commercial Leadership Changes

SAN DIEGO , April 20, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and comm...

11 months ago - PRNewsWire

Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan...

11 months ago - PRNewsWire

Heron Therapeutics Announces New CEO and Board Chairman

Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO , April 3, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage bio...

11 months ago - PRNewsWire

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates

- Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales in 2021 - - APONVIE™ Commercially Launched on March 6, 2023 - - ZYNRELEF ®  Net P...

1 year ago - PRNewsWire

Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023

SAN DIEGO , March 13, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class trea...

1 year ago - PRNewsWire

Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023

SAN DIEGO , March 10, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class trea...

1 year ago - PRNewsWire

Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults

- APONVIE, the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for Postoperative Nausea and Vomiting (PONV) - - APONVIE is d elivered via ...

1 year ago - PRNewsWire

Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference

SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat...

1 year ago - PRNewsWire

Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital

Appoints Three New Independent Directors SAN DIEGO , Feb. 22, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused ...

1 year ago - PRNewsWire

Looking Back At The 10 Most Shorted Stocks Of December 2022

Shorting stocks is still a viable strategy for experienced investors who are active in the stock market. Here is a look back at the most shorted stocks of December 2022.

1 year ago - Forbes

Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises

- Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022, Compared to Annual Net Product Sales in 2021 - - Preliminary Fourth-Quarter 2022 Net Product Sales for ZYN...

1 year ago - PRNewsWire

Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF

- Supplemental New Drug Application Submitted Requesting Expansion of Indication to Broadly Cover Soft Tissue and Orthopedic Surgical Procedures - - Omnibus Spending Bill (H.R. 2617) Includes Provisio...

1 year ago - PRNewsWire

Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference

SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat...

1 year ago - PRNewsWire